ViGeneron presents preclinical data on intravitreal gene therapy of Stargardt disease at ESGCT
Efficient transfer of larger gene via ViGeneron’s proprietary technology platforms REVeRT and vgAAV ViGeneron advances i…
Efficient transfer of larger gene via ViGeneron’s proprietary technology platforms REVeRT and vgAAV ViGeneron advances i…
. 13 neue Kits und Tests ermöglichen die Quantifizierung von AAV-Titern und restlicher Wirtszell-DNA in der Zell- und…
ViGeneron GmbH, a next-generation gene therapy company, today announced a follow-on collaboration with Daiichi Sankyo Co…
Regeneron receives access to ViGeneron’s vgAAV capsids for one inherited retinal disease target and an option for an exc…
- Restructuring Provides Parallel Rights to Manufacture and Sell doggybone DNA (dbDNA™) into the AAV market as Independe…
Der aktuellste Viralen Vektor-und Plasmid-DNA-Herstellung Marktforschungsbericht befasst sich mit einer Reihe von unter…
Wissenschaftlerinnen und Wissenschaftler des Paul-Ehrlich-Instituts (PEI) haben gleich zwei neue Wege aufgezeigt, mittel…
Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, announced…
ViGeneron GmbH, a gene therapy company, today announced a research collaboration to utilize its novel engineered adeno-a…
. - Collaboration with Biogen to develop gene therapy for an undisclosed target to treat inherited eye disease, plus op…